T. Rowe Price Associates, Inc. (I.. recently announced the acquisition of new stake in Aimmune Therapeutics Inc. (NASDAQ:AIMT). The institutional investor has increased its shareholding in the Healthcare company by 1.58% to 5.27 million shares with purchase of 82229.0 shares. This fresh investment now brings its stake to 8.08% valued currently at $69.68 million. In addition, The Vanguard Group, Inc. raised its holdings by 49615.0 to 4.07 million shares. And SSgA Funds Management, Inc. has lifted its position by 69.27% or 1.52 million shares – to 3.73 million shares.
With over 44.61 million Aimmune Therapeutics Inc. (AIMT) shares trading Monday and a closing price of $34.22 on the day, the dollar volume was approximately $1.53 billion. The shares have shown a positive weekly performance of 174.20% and its price on 08/31/20 gained nearly 171.59%. Currently, there are 65.18M common shares owned by the public and among those 50.99M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 11 analysts who have offered their price forecasts for AIMT have a consensus price objective of $31.77. The analysts have set the share’s price value over the next 12 months at a high of $50.00 and a low of $15.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Aimmune Therapeutics Inc. stock is 2.20 for the next 12 months. But an upside of 31.56% will see the stock hit the forecast high price target while mean target price for the stock is $34.50.
Insiders at the company have transacted a total of 41 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 30 of these insider trades were purchases, accounting for 15,077,114 shares. Insider sales of the common stock occurred on 11 occasions, with total insider shares sold totaling 81,687 shares.
The top 3 mutual fund holders in Aimmune Therapeutics Inc. are SPDR S&P Biotech ETF, Eventide Healthcare & Life Scienc, and Catalyst Eventide Gilead Fund. SPDR S&P Biotech ETF owns 3.06 million shares of the company’s stock, all valued at over $40.38 million. The company sold 30618.0 shares recently to bring their total holdings to about 4.68% of the shares outstanding. Eventide Healthcare & Life Scienc bought 0.77 million shares to see its total holdings expand to 2.05 million shares valued at over $27.08 million and representing 3.14% of the shares outstanding. Catalyst Eventide Gilead Fund now owns shares totaling to 2.76% of the shares outstanding.
Shares of Aimmune Therapeutics Inc. (NASDAQ: AIMT) opened at $34.21, up $21.61 from a prior closing price of $12.60. However, the script later closed the day at $34.22, up 171.59%. The company’s stock has a 5-day price change of 174.20% and 95.32% over the past three months. AIMT shares are trading 2.24% year to date (YTD), with the 12-month market performance up to 71.44% higher. It has a 12-month low price of $10.09 and touched a high of $37.00 over the same period. Currently, 44.61 million shares have been traded, compared to an average intraday trading volume of 1.11 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 156.64%, 128.04%, and 61.20% respectively.
Institutional ownership of Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares accounts for 87.20% of the company’s 65.18M shares outstanding. Mutual fund holders own 37.46%, while other institutional holders and individual stakeholders account for 43.79% and 32.67% respectively.
It has a market capitalization of $2.13B and a beta (3y monthly) value of 0.77. The earnings-per-share (ttm) stands at -$4.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.30% over the week and 4.45% over the month.
Analysts forecast that Aimmune Therapeutics Inc. (AIMT) will achieve an EPS of -$0.98 for the current quarter, -$0.98 for the next quarter and -$2.87 for 2021. The lowest estimate earnings-per-share for the quarter is -$1.23 while analysts give the company a high EPS estimate of -$0.88. Comparatively, EPS for the current quarter was -$1.03 a year ago. Earnings per share for the fiscal year are expected to decrease by -8.20%, and 30.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 11 brokerage firm advisors rate Aimmune Therapeutics Inc. (AIMT) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 6 of the 11 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AIMT, a number of firms have released research notes about the stock. Cowen stated their Outperform rating for the stock in a research note on July 13, 2020, with the firm’s price target at $35. H.C. Wainwright coverage for the Aimmune Therapeutics Inc. (AIMT) stock in a research note released on May 12, 2020 offered a Neutral rating with a price target of $15. JMP Securities was of a view on March 18, 2020 that the stock is Mkt Perform, while H.C. Wainwright gave the stock Neutral rating on February 28, 2020, issuing a price target of $33- $30. Wedbush on their part issued Outperform rating on February 03, 2020.